| Tradename | Revcovi |
|---|---|
| Dailymedid | Elapegademase |
| Routes of administration | Intramuscular |
| Atc prefix | L03 |
| Atc suffix | AX21 |
| Legal us | Rx-only |
| Cas number | 1709806-75-6 |
| Drugbank | DB14712 |
| Unii | 9R3D3Y0UHS |
| Kegg | D11017 |
| Chembl | 3990026 |
| Synonyms | elapegademase-lvlr |
Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.[1]
It is a recombinant enzyme[2] that is administered weekly by intramuscular injection.[3]
Elapegademase may interact with PEGylated drugs.[3]
Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.[4][5][6] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[7]
References
- ^ Skidmore-Roth L (2022). "Elapegademase". Mosby's 2023 Nursing Drug Reference. Elsevier Health Sciences. p. 429. ISBN 978-0-323-93330-8.
- ^ "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
- ^ "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
- ^ "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Archived from the original on December 26, 2019. Retrieved 26 December 2019.
- ^ "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
- ^ "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
- ^ "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.
External links
- "Elapegademase". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on February 17, 2025.